相关实验视频
Updated: Jun 14, 2025
10:43
Evaluating In Vitro DNA Damage Using Comet Assay
Published on: October 11, 2017
37.4K
塔拉佐帕里布用于治疗前列腺癌
Arshit Narang1, Chadi Hage Chehade1, Zeynep Irem Ozay1
1Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Expert opinion on pharmacotherapy
|August 30, 2024
概括
PARP 抑制剂为HRR 改变的晚期前列腺癌提供了有前途的治疗方法. 组合疗法,包括PARP抑制剂,显示出改善转移性割抵抗性前列腺癌的结果的潜力.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 大约25%的晚期前列腺癌病例涉及同源重组/DNA损伤修复 (HRR) 途径的改变.
- PARP抑制剂 (PARPi) 在HRR改变的瘤中诱导合成致死性,对转移性割抵抗性前列腺癌 (mCRPC) 和转移性激素敏感前列腺癌 (mHSPC) 显示出希望.
研究的目的:
- 审查PARPi,特别是talazoparib在前列腺癌中的作用机制,药理动力学,药理动力学和临床数据.
- 检查TALAPRO-1,TALAPRO-2和正在进行的TALAPRO-3试验中的临床试验数据.
主要方法:
- 对前列腺癌中PARP抑制剂的现有文献的综述.
- 对临床试验数据 (TALAPRO-1,TALAPRO-2,TALAPRO-3) 的分析.
主要成果:
- PARPi,如talazoparib,在HRR突变患者中显示出对mCRPC和mHSPC的治疗潜力.
- 结合疗法涉及雄激素受体通路抑制剂 (ARPI) 和 PARPi 适用于HRR突变的mCRPC.
结论:
- 尽管取得了进展,但mCRPC仍然是一个重大挑战,突显了对有效疗法的需求.
- 基因组测试对于识别可以从PARPi中受益的患者至关重要,但获取仍然是一个挑战.
- 进一步的研究和改进的基因组测试访问对于优化晚期前列腺癌治疗策略至关重要.
更多相关视频
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K